LuciVemu

Description

COMPOSITION:

Each film-coated tablet contains Vemurafenib…………………………………. 240mg.

INDICATION:

LuciVemu is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

LuciVemu is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.

DOSAGE AND USE:

• Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with LuciVemu.

• Recommended dose: 960 mg orally twice daily taken approximately 12 hours apart with or without a meal.

STORAGE:

I n a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciVemu during Pregnancy and Lactation.